3don MSNOpinion
Why you should be pleased we run trials on nudges, even if you don't like nudges (or trials)
Last year, we ran a randomized controlled trial working with frontline workers in the homelessness sector, which aimed to ...
Objective To determine whether a full-scale randomised control trial (RCT) assessing the efficacy and cost-effectiveness of a ...
The findings are yet another reminder of the remarkable and often unexpected ways that vaccines can protect us well beyond ...
Background Fermented foods are a promising yet underexplored intervention for influencing brain function and mental health through the gut–brain axis. Objective The objective of this study was to ...
1don MSN
US awards no-bid contract to Denmark scientists studying hepatitis B vaccine in African babies
The Trump administration has awarded a $1.6 million, no-bid contract a Danish university to study hepatitis B vaccinations on ...
Introduction Implementation of low-intensity, evidence-based psychological interventions can help meet the mental health and ...
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2DHIGH POINT, N.C., Dec. 18, 2025 ...
The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...
The sharp rise in gender dysphoria among adolescents is a relatively recent development. American medical organizations promote a single treatment pathway — “ gender-affirming care ” as the presumed ...
MedPage Today on MSN
CDC Gives Danish Researchers $1.6M to Study Hep B Vaccine Birth Dose in Africa
Researchers have raised concerns about an unusual federal grant made to Danish researchers to study the hepatitis B vaccine birth dose in Africa. The CDC awarded $1.6 million over 5 years to an ...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid ...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results